ID   TK-ALCL1
AC   CVCL_E2T4
RX   PubMed=38755432;
CC   Population: Japanese.
CC   Doubling time: 26.9 +- 0.4 hours (PubMed=38755432).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:7910; NPM1; Name(s)=NPM1-ALK (PubMed=38755432).
CC   Derived from site: In situ; Axillary lymph node; UBERON=UBERON_0001097.
ST   Source(s): PubMed=38755432
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 9,10
ST   D21S11: 32,32.2
ST   D5S818: 12
ST   D7S820: 9.3,10,10.3,11
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 14,19,20
DI   NCIt; C37193; Anaplastic large cell lymphoma, ALK-positive
DI   ORDO; Orphanet_300895; ALK-positive anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 19-12-24; Version: 2
//
RX   PubMed=38755432; DOI=10.1007/s13577-024-01077-8;
RA   Sungwan P., Panaampon J., Kariya R., Kamio S., Nakagawa R., Hirozane T.,
RA   Ogura Y., Abe M., Hirabayashi K., Fujiwara Y., Kikuta K., Okada S.;
RT   "Establishment and characterization of TK-ALCL1: a novel
RT   NPM-ALK-positive anaplastic large-cell lymphoma cell line.";
RL   Hum. Cell 37:1215-1225(2024).
//